Current Report Articles
Report on Cost to U.S. of PhRMA Strategies to Circumvent Generic Competition
Report (Sept. 18, 2020) – A report commissioned by the Coalition for Affordable Prescription Drugs describes one tactic – "product hopping" – that name-brand drug manufacturers used to circumvent generic competition by tweaking product formulations, costing the U.S. health system an estimated $4.7 billion annually for just five products. Product hopping is described in the report as a strategy used to extend the patent life of brand name products without making clinically significant changes.
--Karen Braman